VistaGen Therapeutics (NASDAQ: VTGN) Featured Research Report

4 A EGIS C APITAL C ORP. Background VistaGen was founded by H. Ralph Snodgrass, Ph.D. in 1998, and underwent a change in focus (e.g. from stem cell-based treatments to anxiety, depression, and certain CNS disorders) in 2014. VistaGen’s subsidiary, VistaStem, maintains a focus on pluripotent stem cell technology. The company is helmed by Shawn Singh, CEO and Director, with Dr. Snodgrass serving as President, CSO, and Director, and Mark Smith, M.D., Ph.D. serving as CMO. Jerrold Dotson serves as the company’s CFO. VistaGen has assembled a clinical and regulatory advisory board and a scientific advisory board, discussed in depth later in this report. Chairing the company’s clinical and regulatory advisory board is Maurizio Fava, M.D., and the board is rounded-out by several highly accomplished members, including Michael Liebowitz, M.D. VistaGen is developing multiple clinical assets, and undertaking pre-clinical work as well, across numerous psychiatric and CNS indications, discussed in-depth in this report. VistaGen Therapeutics, Inc. October 8, 2020